10-Q
Quarterly Report
Actuate Therapeutics, Inc.
ACTU
NASDAQ
CIK: 1652935
File #: 001-42139
Balance Sheet
30 line items · 2 periods
XBRL
| Item | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
ASSETS | ||
Current assets: | ||
Cash and Cash Equivalents | 8,134,004 | 13,159,423 |
Other Non-Operating Current Assets | 385,444 | 483,996 |
Total current assets | 8,519,448 | 13,643,419 |
Other Non-Operating Non-Current Assets | 391,838 | 392,491 |
Total assets | 8,911,286 | 14,035,910 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Current liabilities: | ||
Accounts Payable | 1,201,393 | 1,524,190 |
Other Non-Operating Current Liabilities | 2,602,611 | 3,567,404 |
Accrued Clinical Study Costs | 2,365,362 | 3,169,433 |
Other Accrued Expenses | 237,249 | 397,971 |
Other Current Liabilities | 885,813 | 588,304 |
Other Non-Operating Current Liabilities | 32,080 | 27,018 |
Total current liabilities | 4,721,897 | 5,706,916 |
Long term liabilities: | ||
License payable | 404,991 | 404,991 |
Total long-term liabilities | 404,991 | 404,991 |
Total liabilities | 5,126,888 | 6,111,907 |
Stockholders’ equity: | ||
Preferred Stock | 0 | 0 |
Total Stockholders' Equity | 24 | 23 |
Total Stockholders' Equity | 164,017,824 | 162,531,681 |
Total Stockholders' Equity | (160,233,450) | (154,607,701) |
Total stockholders’ equity | 3,784,398 | 7,924,003 |
Common Stock | 24 | 23 |
Additional Paid-in Capital | 164,017,824 | 162,531,681 |
Retained Earnings | (160,233,450) | (154,607,701) |
Total liabilities and stockholders’ equity | 8,911,286 | 14,035,910 |